September 2023 in “SKIN The Journal of Cutaneous Medicine” This case report documented a 74-year-old female with alopecic patches and other skin issues during talquetamab therapy for multiple myeloma, suggesting that the drug may cause skin-related adverse effects due to reactivity to GPRC5D-expressing structures.
30 citations
,
April 2007 in “Journal of Leukocyte Biology” This study found that anti-CD44 treatment inhibited leukocyte migration in alopecia areata and eczema, suggesting targeted therapies could enhance contact sensitizer treatment for alopecia areata.
August 2024 in “Frontiers in Pharmacology” This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.
May 2025 in “The Journal of Rheumatology” In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.
1 citations
,
May 2025 in “The Journal of Rheumatology” In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.